NCT03427060View on ClinicalTrials.gov

Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms

PHASE2CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

May 14, 2018

Primary Completion Date

November 15, 2018

Study Completion Date

February 3, 2021

Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
DRUG

Coversin

Coversin - 22.5mg followed by 45mg for 6 months.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Lead Sponsor

AKARI Therapeutics
All Listed Sponsors
lead

AKARI Therapeutics

INDUSTRY